AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26489933 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-inflated truncated normal observation model
Number of subjects: 24
Study 26490042 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MRI set-up and prolonged Holter-ECG monitoring
Number of subjects: 475
Study 26490042 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic care (including stroke unit monitoring for at least 24 h, echocardiography, and ultrasound of brain-supplying arteries)
Number of subjects: 475
Study 26490042 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MRI approach and prolonged ECG monitoring
Number of subjects: 475
Study 26490100 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmolarity equation: osmolarity=1.86×(Na++K+)+1.15×glucose+urea+14 (all measured in mmol/L)
Number of subjects: 595
Study 26490100 — intervention group
Group type: COMPARATOR
Intervention: 39 osmolarity equations calculated using serum indices from the same blood draw as directly measured osmolality
Number of subjects: 595
Study 26490100 — intervention group
Group type: EXPERIMENTAL
Intervention: Best equation identified
Number of subjects: 595
Study 26490103 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase-beta (1 mg/kg/2 weeks) with antiproteinuric therapy (ACE inhibitors or ARBs)
Number of subjects: 24
Study 26490103 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not achieving UPCR goal)
Number of subjects: 24
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure (EE) measured by doubly labeled water before and during cycling (17 ± 1 MJ/d before vs 30 ± 2 MJ/d during; P < 0.001)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (EI) recorded during cycling (25 ± 1 MJ/d)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat change measured (-2.2 ± 0.7 kg; P = 0.02)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass change measured (2.5 ± 0.6 kg; P = 0.01)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger ratings recorded twice daily (both P = 0.02)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fullness ratings recorded (P = 0.04)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of insulin increased by 120% ± 15% (P = 0.02)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of glucagon-like peptide 1 (GLP-1) increased by 60% ± 20% (P < 0.01)
Number of subjects: 6
Study 26490491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of Polypeptide YY(3-36) increased by 80% ± 30% (P < 0.02)
Number of subjects: 6
Study 26490495 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain (GWG)
Number of subjects: 302
Study 26490566 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 54
Study 26490566 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (MPA)
Number of subjects: 54
Study 26490566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 54
Study 26490566 — intervention group
Group type: COMPARATOR
Intervention: Participants with healthy CRF
Number of subjects: 54
Study 26490645 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA)
Number of subjects: 25
Study 26491110 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk score based on age, sex, peak aortic velocity (Vmax), high-sensitivity troponin I concentration, and electrocardiographic strain pattern.
Number of subjects: 147
Study 26491799 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration and transfusion threshold
Number of subjects: 200
Study 26492842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux alone
Number of subjects: 17
Study 26492842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phonation and reflux events
Number of subjects: 17
Study 26492842 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent phonation and reflux
Number of subjects: 17
Study 26492842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux events
Number of subjects: 17
Study 26492847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose challenge test (25 g lactulose in a liquid breakfast of 400 mL Nutridrink)
Number of subjects: 100
Study 26492921 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with atropine (1 mg bolus 45 min before MSF + 80 ng·kg(-1)·min(-1) for 2 h)
Number of subjects: 10
Study 26492921 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 10
Study 26492921 — intervention group
Group type: COMPARATOR
Intervention: Atropine + clamp + MSF
Number of subjects: 10
Study 26492921 — intervention group
Group type: EXPERIMENTAL
Intervention: MSF
Number of subjects: 10
Study 26493200 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition endoscopy with digital chromoendoscopy
Number of subjects: 224
Study 26493200 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition endoscopy with digital chromoendoscopy (high-confidence predictions)
Number of subjects: 224
Study 26493637 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 19
Study 26493637 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 19
Study 26493661 — intervention group
Group type: COMPARATOR
Intervention: Household disposable income quintiles (1st quintile as control)
Number of subjects: 100534
Study 26493785 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cfDNA concentration (highest tertile)
Number of subjects: 218
Study 26493785 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased baseline cfDNA concentration
Number of subjects: 218
Study 26493785 — intervention group
Group type: COMPARATOR
Intervention: cfDNA concentration
Number of subjects: 218
Study 26493933 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPAS system (transobturator posterior anal sling)
Number of subjects: 152
Study 26493938 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts greater than 400 cells per μL
Number of subjects: 130248
Study 26493938 — intervention group
Group type: COMPARATOR
Intervention: Blood eosinophil counts of 400 cells per μL or less
Number of subjects: 130248
Study 26494259 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas(®) EGFR Mutation Test
Number of subjects: 110
Study 26494259 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAMing digital PCR
Number of subjects: 110
Study 26494259 — intervention group
Group type: EXPERIMENTAL
Intervention: Droplet Digital™ PCR
Number of subjects: 110
Study 26494259 — intervention group
Group type: EXPERIMENTAL
Intervention: therascreen™ EGFR amplification refractory mutation system assay
Number of subjects: 110
Study 26494259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple platforms
Number of subjects: 110
Study 26494395 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 26495926 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist snuff consumers (MSC)
Number of subjects: 3
Study 26495926 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (SMK)
Number of subjects: 3
Study 26495926 — intervention group
Group type: COMPARATOR
Intervention: Non-tobacco consumers (NTC)
Number of subjects: 3
Study 26495947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) using ClearPoint interventional MRI-guided methodology
Number of subjects: 26
Study 26496767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant-primed glucagon stimulation test (PegV-GST)
Number of subjects: 10
Study 26496767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (single dose)
Number of subjects: 10
Study 26496767 — intervention group
Group type: COMPARATOR
Intervention: Glucagon stimulation test (GST)
Number of subjects: 10
Study 26496767 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 10
Study 26497081 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir (12 weeks, up to 16 weeks); 169 patients received ribavirin
Number of subjects: 836
Study 26497081 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir with ribavirin
Number of subjects: 836
Study 26497081 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir
Number of subjects: 836
Study 26497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 5 mg/m(2)/day for 5 consecutive days with 4-week intervals, individualized doses for Cycles 2 to 4 based on pharmacokinetic-pharmacodynamic modeling.
Number of subjects: 15
Study 26497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (individualized doses for Cycles 2 to 4)
Number of subjects: 15
Study 26497198 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial doses for cohorts 2 to 5 were 4, 5, 5.5, and 5 mg/m(2)/day, respectively; median maintenance dose was 7 mg/m(2)/day.
Number of subjects: 15
Study 26497302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifungal DNA-microarray and Aspergillus specific PCR
Number of subjects: 133
Study 26497302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifungal DNA-microarray
Number of subjects: 133
Study 26497307 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative patient website, patient leaflet, follow-up consultation
Number of subjects: 12
Study 26497307 — intervention group
Group type: EXPERIMENTAL
Intervention: Team training, checklists/flowcharts
Number of subjects: 12
Study 26497307 — intervention group
Group type: COMPARATOR
Intervention: Lack of information given by professionals
Number of subjects: 12
Study 26497307 — intervention group
Group type: COMPARATOR
Intervention: Lack of clarity of the guidelines, lack of knowledge, failing team-communication
Number of subjects: 12
Study 26497345 — intervention group
Group type: EXPERIMENTAL
Intervention: Open simple prostatectomy
Number of subjects: 0
Study 26497345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simple prostatectomy
Number of subjects: 0
Study 26497345 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic simple prostatectomy
Number of subjects: 0
Study 26497345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral approaches with photon-based energy sources (i.e. laser prostatectomy)
Number of subjects: 0
Study 26497660 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs6599230 and rs6843082
Number of subjects: 400
Study 26497660 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs1448817 and rs7193343
Number of subjects: 400
Study 26497660 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs1448817, rs17042171, rs3807989, and rs6843082
Number of subjects: 400
Study 26497660 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs rs17375901 and rs7193343
Number of subjects: 400
Study 26497750 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) infection
Number of subjects: 487247
Study 26497750 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) infection in persons aged 65+ years
Number of subjects: 487247
Study 26497750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk elderly
Number of subjects: 487247
Study 26497750 — intervention group
Group type: COMPARATOR
Intervention: RSV compared to influenza
Number of subjects: 487247
Study 26497813 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 29
Study 26498178 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 73
Study 26498178 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group with pregnancy complications
Number of subjects: 73
Study 26498178 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 73
Study 26498869 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 102
Study 26499223 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute device
Number of subjects: 100
Study 26499500 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance (IMR)
Number of subjects: 1096
Study 26499500 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of high IMR
Number of subjects: 1096
Study 26499500 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of FFR ≤0.80
Number of subjects: 1096
Study 26499927 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of galectin-9 above 690 pg/mL
Number of subjects: 149
Study 26499927 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of galectin-9
Number of subjects: 149
Study 26499927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of galectin-9 level and Model For End-Stage Liver Disease score
Number of subjects: 149
Study 26499927 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time measurement of plasma galectin-9 level
Number of subjects: 149
Study 26499927 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk analyses of galectin-9 levels
Number of subjects: 149
Study 26500330 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM and mild/no DPN
Number of subjects: 34
Study 26500330 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM and severe DPN
Number of subjects: 34
Study 26500330 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 26500330 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM (both mild/no DPN and severe DPN)
Number of subjects: 34
Study 26500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential scheme (9 cycles of VMP followed by 9 cycles of Rd; n = 118)
Number of subjects: 233
Study 26500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating scheme (1 cycle of VMP followed by 1 cycle of Rd, up to 18 cycles; n = 115)
Number of subjects: 233
Study 26500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential scheme
Number of subjects: 233
Study 26500339 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating scheme
Number of subjects: 233
Study 26500686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 44
Study 26500686 — intervention group
Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 44
Study 26500687 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet for 8 weeks
Number of subjects: 48
Study 26501540 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Concentrate Storage
Number of subjects: 0
Study 26501758 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunction assessment
Number of subjects: 100
Study 26501758 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic dysfunction severity score (SDSS)
Number of subjects: 100
Study 26501758 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of initial newborn assessment and research examination
Number of subjects: 100
Study 26502812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ1-42
Number of subjects: 403
Study 26502812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ1-40
Number of subjects: 403
Study 26502894 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing (NGS) assay
Number of subjects: 101
Study 26503201 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) doses of greater than 80.5 Gy (median, 58.05 Gy)
Number of subjects: 79
Study 26503201 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) doses of lower than 80.5 Gy
Number of subjects: 79
Study 26503201 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) doses of greater than 80.5 Gy
Number of subjects: 79
Study 26503453 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge communication content as defined by physicians (34 items selected from 81)
Number of subjects: 51
Study 26503453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic acronym 'InFARcT' for structuring discharge information
Number of subjects: 51
Study 26503811 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Number of subjects: 0
Study 26503811 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer daylight exposure (SDE)
Number of subjects: 0
Study 26503811 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression networks
Number of subjects: 0
Study 26504108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 373
Study 26504108 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon (CB) ablation
Number of subjects: 373
Study 26504182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus as monotherapy
Number of subjects: 30
Study 26504524 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation for 4 weeks
Number of subjects: 47
Study 26504524 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation for 4 weeks
Number of subjects: 47
Study 26504524 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation for an additional 17 weeks
Number of subjects: 47
Study 26506129 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26506270 — intervention group
Group type: EXPERIMENTAL
Intervention: ENROUTE Transcarotid NPS during carotid artery stenting (CAS) procedures
Number of subjects: 208
Study 26506438 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV-13)
Number of subjects: 30
Study 26507708 — intervention group
Group type: EXPERIMENTAL
Intervention: Amb a sublingual immunotherapy tablet
Number of subjects: 452
Study 26507708 — intervention group
Group type: EXPERIMENTAL
Intervention: Amb a extract
Number of subjects: 452
Study 26507836 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly
Number of subjects: 22
Study 26507836 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK2866 (0.1 mg/kg)
Number of subjects: 22
Study 26507836 — intervention group
Group type: EXPERIMENTAL
Intervention: KHK2866 (all doses)
Number of subjects: 22
Study 26507877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 30
Study 26508138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (200-mg extended-release tablets)
Number of subjects: 35
Study 26508138 — intervention group
Group type: EXPERIMENTAL
Intervention: O-desmethyltramadol (ODM)
Number of subjects: 35
Study 26508901 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy without ifosfamide/etoposide
Number of subjects: 1444
Study 26508901 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, treatment, tumor location, and tumor size
Number of subjects: 1444
Study 26508901 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1444
Study 26509071 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids >5 mg/day
Number of subjects: 838
Study 26509071 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids ≤5 mg/day
Number of subjects: 838
Study 26509071 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued corticosteroid treatment
Number of subjects: 838
Study 26509074 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409
Study 26509766 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscope-integrated optical coherence tomography (MIOCT)
Number of subjects: 2
Study 26510020 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice a day
Number of subjects: 50
Study 26510696 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment (mean duration 1 year, mean INR 1.9 for IPAH, 2.0 for SSc-PAH)
Number of subjects: 374
Study 26510696 — intervention group
Group type: COMPARATOR
Intervention: Warfarin-naïve patients (matched control group)
Number of subjects: 374
Study 26510775 — intervention group
Group type: EXPERIMENTAL
Intervention: PlayForward: Elm City Stories (videogame intervention)
Number of subjects: 166
Study 26511221 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel oral anticoagulants (NOACs) administered intermittently based on ICM guidance
Number of subjects: 59
Study 26511221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent NOAC administration
Number of subjects: 59
Study 26511224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-fucopentaose (LNFP) I
Number of subjects: 25
Study 26511224 — intervention group
Group type: EXPERIMENTAL
Intervention: Disialyl-lacto-N-tetraose
Number of subjects: 25
Study 26511224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-fucopentaose II (LNFPII)
Number of subjects: 25
Study 26511224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosyl-disialyl-lacto-N-hexaose
Number of subjects: 25
Study 26511224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose
Number of subjects: 25
Study 26511652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorinated (19F) agent CS-1000 labeled SVF cells
Number of subjects: 0
Study 26511835 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (PM1 concentration at 314 μg/m(3) for 3 hours)
Number of subjects: 14
Study 26511835 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 14
Study 26511835 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure (control)
Number of subjects: 14
Study 26511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-adrenomedullin (ProADM)
Number of subjects: 7132
Study 26511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 7132
Study 26511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 7132
Study 26511896 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloons (DEBs)
Number of subjects: 44
Study 26511896 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 44
Study 26511896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DEBs and BA
Number of subjects: 44
Study 26511934 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind repositioning techniques (withdrawn into the trachea and blindly readvanced without rotation, or with 90° or 180° counterclockwise rotation while the patient's head was turned right)
Number of subjects: 1135